TABLE 4

Doses for 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab Compared with 177Lu-Lilotomab Satetraxetan

Organ90Y-ibritumomab tiuxetan (Gy)*131I-tositumomab (Gy)†177Lu-lilotomab satetraxetan (20 MBq/kg) + lilotomab predosing (Gy)
Liver5.762.561.55
Spleen11.283.564.50
Kidney0.126.100.74
WB0.600.750.22
Red marrow or marrow space1.562.031.46

  • ↵* An 80-kg patient and a 15 MBq/kg administered activity are assumed (28).

  • ↵† An administered activity to limit WB dose to 0.75 Gy is assumed (32).